286 related articles for article (PubMed ID: 9861837)
1. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Mycoses; 1998; 41(7-8):309-19. PubMed ID: 9861837
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
Wildfeuer A; Seidl HP; Paule I; Haberreiter A
Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
[TBL] [Abstract][Full Text] [Related]
3. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
Marco F; Pfaller MA; Messer SA; Jones RN
Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
5. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
6. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
Espinel-Ingroff A; Johnson E; Hockey H; Troke P
J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
[TBL] [Abstract][Full Text] [Related]
7. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
Espinel-Ingroff A
J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.
Cuenca-Estrella M; Gomez-Lopez A; Mellado E; Buitrago MJ; Monzon A; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2006 Mar; 50(3):917-21. PubMed ID: 16495251
[TBL] [Abstract][Full Text] [Related]
10. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
Oakley KL; Moore CB; Denning DW
J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
[TBL] [Abstract][Full Text] [Related]
12. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
Espinel-Ingroff A; Boyle K; Sheehan DJ
Mycopathologia; 2001; 150(3):101-15. PubMed ID: 11469757
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
Espinel-Ingroff A
J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
[TBL] [Abstract][Full Text] [Related]
16.
Singh SK; Patwa DK; Tilak R; Das A; Singh TB
Indian J Dermatol Venereol Leprol; 2019; 85(4):388-392. PubMed ID: 30950409
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
18. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
[TBL] [Abstract][Full Text] [Related]
19. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of voriconazole against selected fungi.
McGinnis MR; Pasarell L; Sutton DA; Fothergill AW; Cooper CR; Rinaldi MG
Med Mycol; 1998 Aug; 36(4):239-42. PubMed ID: 9776841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]